Introduction
Ischemic heart disease (IHD, also known as coronary heart disease) is the most common type of cardiovascular disease, is the leading cause of death worldwide, and places a huge burden on the individual, family, and community. [1] [2] [3] There were 7,249,000 deaths resulting from IHD worldwide in 2008, accounting for 12.7% of total global mortality. 1 Worldwide, there is over 20-fold variation in IHD mortality rates between countries. 4 In the USA, IHD is the leading cause of mortality, resulting in over 500,000 deaths every year. 1, 4 In the People's Republic of China, IHD is the second leading cause of cardiovascular disease-related death, accounting for 22% of cardiovascular deaths in urban areas and 13% in rural areas. 5 In the past few decades, although there has been great improvement in our understanding of the etiology of IHD and advances in the diagnostics and therapeutics for IHD, the disease remains a major clinical challenge with lifethreatening outcomes. Therefore, there is an urgent need for new agents and novel therapeutic approaches in the treatment of IHD to reduce the mortality and improve quality of life for patients with IHD.
Accumulating evidence shows that apoptosis is an important contributing factor in the development and progression of IHD. 6, 7 The balance between proapoptotic and antiapoptotic proteins is critical to maintain the cellular status of cardiomyocytes. Apoptosis can augment ischemic conditions. The B-cell lymphoma 2 (Bcl-2) protein family is a determining factor in the commitment of cells to apoptosis. 8 Manipulation of apoptosis by regulating the Bcl-2 family has been proposed to be a promising strategy for the treatment of many diseases, including IHD and cancer. 8 Furthermore, the caspase family, aspartate-specific cysteine proteases, and members of the interleukin-1β-converting enzyme family, are closely associated with apoptosis and have an important role in the induction, transduction, and amplification of intracellular apoptotic signals. 9, 10 Caspases can be regulated by Bcl-2 family proteins, calpain, and calcium ions. 9, 10 It has been reported that targeting caspase 3 may represent an attractive approach to attenuate or reverse heart failure. 9, 10 However, the therapeutic effect and safety of the abovementioned approaches in the treatment of cardiovascular diseases need to be confirmed.
There is increasing evidence showing that natural products have substantial therapeutic effects on cardiovascular diseases, including IHD. Huo Luo Xiao Ling Dan (HLXLD) is a classic prescription that has been documented in "Records of Tradition Chinese and Western Medicine in Combination" since the Qing Dynasty. 11 HLXLD consists of Radix Salvia miltiorrhiza, Angelica sinensis, Gummi olibanum, and Commiphora myrrha. It has a wide range of pharmacological activity, [12] [13] [14] [15] [16] [17] such as removing blood stasis, relieving cold pain in the heart and abdomen, ameliorating back pain or lumbago, sprains, and bruises, improving internal and external sores and ulcers, and decreasing lump accumulation in the abdomen. In recent years, increasing evidence suggests that HLXLD may be effective for the treatment of IHD, such as coronary atherosclerotic cardiopathy, due to the numerous pharmacologically active components, such as ferulic acid, ligustilide, succinic acid, vanillic acid, tanshinones, danshensu, salvianolic acids, protocatechuic aldehyde, and β-boswellic acid. 18, 19 However, mechanistic and functional studies of the therapeutic effects and targets of HLXLD in IHD are still sparse. In particular, there is a lack of investigation of the molecular interactions between the major active components of HLXLD and apoptotic regulators and the regulating effect of HLXLD on apoptosis in IHD. In the present study, we aimed to predict the molecular interactions between the major active components of HLXLD and apoptotic regulators and to examine the therapeutic effect of HLXLD in a rat model of acute myocardial ischemia induced by coronary artery ligation. of ADMET and their rules. Absorption levels ranged from 0, 1, 2, to 3, indicating good, moderate, low, or very low absorption, respectively. The predicted aqueous solubility level was classified into extremely low (0), no, very low, but possible (1), yes, low (2) , yes, good (3), yes, optimal (4), no, too soluble (5) , and warning, molecules with one or more unknown AlogP98 types (6) . The predicted blood-brain barrier permeability levels included very high (0), high (1), medium (2) , low (3), undefined (4) , and warning, molecules with one or more unknown AlogP calculation (5) . There are two predicted classes of CYP2D6 ligand, ie, noninhibitor (0) and inhibitor (1) . The predicted hepatotoxicity was categorized into nontoxic (0) and toxic (1) 
herbal preparation
A. sinensis, G. olibanum, and C. myrrha (500 g each) were mixed and dissolved in distilled water (1:10, w/v). A 9-mL aliquot of volatile oil was extracted from the mixture. Next, 240 g of powder was obtained from the aqueous solution of Chinese angelica, frankincense, and myrrh mixture. Salvia miltiorrhiza (500 g) was dissolved in alcohol (1:10, w/v) and heated under reflux for 1 hour, and 500 mL of alcoholic extraction was collected by centrifuging at 3,000× g for 30 minutes. The residues were dissolved in water (1:10, w/v). The water solution was heated under reflux for 1 hour twice, and the resulting liquids were combined with the previous extractions. The mixture was then concentrated by centrifugation to 250 mL. The extracts of the drugs were mixed into a suspension and diluted with distilled water to prepare the low-dose (2.7 g/kg), mid-dose (5.4 g/kg), and high-dose (10.8 g/kg) test.
animals
Male Sprague-Dawley rats (200-250 g, aged 6-8 weeks) were provided by the Experimental Animal Center of Shanghai University of Traditional Chinese Medicine. The rats were housed in the accredited animal housing facility under controlled temperature (22°C±2°C) and a 12-hour dark/ light cycle. All rats were allowed to acclimate for 5-7 days prior to the experiments. All experiments were conducted according to the animal protocol approved by the animal ethics committee of Shanghai University of Traditional Chinese Medicine.
animal experiment
In order to examine the effect of HLXLD on IHD in rats, we first performed coronary artery ligation to establish an acute myocardial ischemic rat model using thoracotomy. Briefly, the animals were anesthetized by intraperitoneal injection of 25% urethane (1.25 g/kg) and then placed in a dorsal position with limbs been fixed. Thoracotomy was then performed and coronary artery ligation was achieved by inserting a needle 2 mm below the bottom of the left auricula sinistra. The chest was quickly closed and the incision was sutured. The rats were monitored by an animal electrocardiogram machine. Establishment of the model was considered successful with one of following conditions: horizontal shifts of the ST-segment downward or upward by 0.1 mV; T-wave elevation over 1/2 of the R wave in the same lead; T-wave elevation accompanied by ST-segment shifts; oblique or horizontal shifts of ST-segment 0.1 mV; and a flat low pattern or two-way inversion of the T-wave. The established animal models were randomly divided into five groups (n=8), including a model group, a positive control group (isosorbide mononitrate tablets), and groups treated with HLXLD 2.7, 5.4, or 10.8 g/kg. Additionally, a sham operation group of rats underwent thoracotomy with insertion of a line but no Drug Design, Development and Therapy 2015:9 submit your manuscript | www.dovepress.com
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hlXlD ameliorates ischemia-induced myocardial damage coronary artery ligation. After surgery, each animal was administered sodium penicillin (40,000 U/day) by intramuscular injection for 3 consecutive days to prevent postoperative infection. At 24 hours post surgery, all experimental groups were given the test drug by intragastric administration once a day for 4 weeks. The model control group and sham operation group were given the same volume of distilled water by intragastric administration. After 4 weeks, the animals were fasted for 12 hours and then anesthetized. The left and right carotid arteries were separated and a PE-50 polyethylene catheter containing 50 units/mL heparin sodium solution was inserted. The animals were connected to a physiological recorder via a pressure transducer for recording the changes in electrocardiography and pressure. Hemodynamic parameters, including heart rate, mean arterial pressure (MAP), left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), and maximum rate of left ventricular pressure rise and fall (±dp/dt max ) were measured and recorded. Thereafter, blood specimens were collected from the carotid artery. Serum was separated by centrifugation at 300× g and then used for CK, LDH, and SOD assays. Additionally, tissue specimens were taken from the left ventricle and divided into two parts for Western blotting assay and morphologic examination.
Measurement of selected enzymes in rat plasma
The blood samples were collected from the carotid artery and separated by centrifugation at 300× g. The effect of HLXLD in rats with coronary artery ligation-induced acute myocardial ischemia was evaluated by examining plasma levels of SOD, CK, and LDH. Assay kits for SOD, CK, and LDH were used to measure their levels in blood according to the manufacturer's instructions.
histopathological examination
To examine the effect of HLXLD on the morphology of cardiomyocytes, left ventricle tissue samples were collected for routine histopathological examination as previously described. 22 The tissue samples were fixed with formalin, embedded in paraffin, and sectioned. Sections 4 μm thick were stained with hematoxylin and eosin and observed under light microscopy (Nikon Eclipse 50i™; Kanagawa, Japan). Magnification was 40×.
Western blotting assay
The expression levels of rat heart caspase 3 and Bcl-2 were determined using the Western blotting assay as described previously. 23 Samples of rat left ventricle tissue (5 mg each) were washed with pre-cold phosphate-buffered saline and homogenated in 200 μL of RIPA buffer containing a protease inhibitor cocktail. The supernatant was collected twice via centrifugation at 15,000× g for 15 minutes at 4°C. The protein concentration were measured by a bicinchoninic acid protein assay kit. An equal amount of protein sample (20 μg) was electrophoresed on 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) mini-gel after thermal denaturation for 5 minutes at 95°C. The proteins were transferred onto a methanol-activated polyvinylidene difluoride membrane at 100 V for 2 hours at 4°C. Subsequently, the membranes were blocked with 5% skim milk and probed with primary antibodies to caspase 3 and Bcl-2 overnight at 4°C and then incubated with the respective secondary antibody. Visualization was performed using an infrared fluorescence scanning and imaging system (Li-Cor Biosciences Inc., Lincoln, NE, USA). The protein level was normalized to the matching densitometric value of GAPDH.
statistical analysis
The results are expressed as the mean ± standard deviation.
Comparison of means between groups was performed using one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison. A value of P0.05 was considered to be statistically significant.
Results
hlXlD components interact with human
Bcl-xl, Bak1, Bcl-2, procaspase 3, and caspase 9
Following the prediction and validation of the molecular targets, we examined the possible interactions between ferulic acid, ligustilide, succinic acid, vanillic acid, tanshinone IIA, tanshinone IIB, danshensu, salvianolic acid A, salvianolic acid B, salvianolic acid C, protocatechuic aldehyde, and β-boswellic acid with human Bcl-xl, Bak1, Bcl-2, procaspase 3, and caspase 9 using the Discovery Studio ® program 3.1. Ferulic acid, ligustilide, succinic acid, vanillic acid, tanshinone IIA, tanshinone IIB, danshensu, salvianolic acid A, salvianolic acid C, protocatechuic aldehyde, and β-boswellic acid were easily docked into the active sites of human Bcl-xl, Bak1, Bcl-2, procaspase 3, or caspase 9, except for salvianolic acid B.
As shown in Table 1 , the CDOCKER interaction energy ranged from -3.43985 to 33.9346 kcal/mol between ferulic acid and human Bcl-xl, Bak1, Bcl-2, procaspase 3, and caspase 9 ( Table 1 Molecular interactions between ferulic acid, ligustilide, succinic acid, vanillic acid, tanshinone iia, tanshinone iiB, danshensu, salvianolic acid a, salvianolic acid B, salvianolic acid c, protocatechuic aldehyde, and β-boswellic acid and human Bcl-xl, Bak1, Bcl-2, procaspase 3, and caspase 9 using Discovery studio ® program 3. 
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hlXlD ameliorates ischemia-induced myocardial damage with human Bcl-xl via hydrogen bond formation, charge interaction, and π-π interaction with Leu108, Arg102, and Phe105 at the active site, respectively ( Figure 2 ). There was a charge interaction and π-π interaction between ferulic acid and Bak1 with Glu33 and Phe40, respectively. Ferulic acid interacted with procaspase 3 via hydrogen bond formation and charge interaction at Lys159, and ferulic acid bound to caspase 9 via hydrogen bond formation at Arg180 and Gln285 and charge interaction at Arg180, Gln285, and Ser287 ( Figure 2 ). In contrast, there was no hydrogen bond formation, charge interaction, or π-π interaction between ferulic acid and Bcl-2 ( Figure 2 ). Ligustilide was able to be docked into the active sites of human Bcl-xl, Bak1, Bcl-2, procaspase 3, and caspase 9 (Table 1 and Figure 3A -E). The CDOCKER interaction energy ranged from -15.9741 to 25.9178 kcal/mol. Ligustilide bound to Bak1 and Bcl-2 via π-π interaction at Phe40 and hydrogen bond formation at Phe195, respectively ( Figure 3 ). Ligustilide also interacted with procaspase 3 via hydrogen bond formation and π-π interaction at Arg15 (Figure 3 ). There was no hydrogen bond formation, charge interaction, or π-π interaction between ligustilide and Bcl-xl and caspase 9 ( Figure 3 ).
As shown in Table 1 , the CDOCKER interaction energy ranged from 17.7988 to 40.3633 kcal/mol between succinic acid and human Bcl-xl, Bak1, Bcl-2, procaspase 3, and caspase 9 (Table 1 and Figure 4A -E). Succinic acid bound to human Bcl-xl and Bak1 via charge interaction with Arg102 and Glu33 at the active sites, respectively ( Figure 4 ). Succinic acid interacted with procaspase 3 via formation of two hydrogen bonds at Asn37 and Gly38 and two charge interactions at Arg15. Moreover, there were three hydrogen bonds formed between succinic acid and caspase 9 at O-Arg180, O-Gln285, and O-Ser287, and there were three charge interactions between succinic acid caspase 9 at O-Arg178, O-Arg180, and O-Gln285 (Figure 4 ). Succinic acid was docked into the active site of Bcl-2 without hydrogen bond formation, charge interaction, or π-π interaction (Figure 4) .
Vanillic acid was docked into the active sites of human Bcl-xl, Bak1, Bcl-2, procaspase 3, and caspase 9, with the CDOCKER interaction energy ranging from 16.0496 to 33.0769 kcal/mol (Table 1 and Figure 5A -E). Vanillic acid bound to Bak1 via hydrogen bond formation at Phe111 and charge interaction at Leu118. There were four hydrogen bonds formed between vanillic acid and procaspase 3 at Gly12, Arg15, Gly18, and Asn90. Vanillic acid also interacted with procaspase 3 via charge interaction and π-π stacking at Arg15 ( Figure 5 ). There was hydrogen bond formation at Arg180 and two charge interactions at Arg178 and Arg180 between vanillic acid and caspase 9. There was no hydrogen bond formation, charge interaction, or π-π interaction between vanillic acid and Bcl-xl and Bcl-2 ( Figure 5 ).
Tanshinone IIA interacted with human Bcl-xl, Bak1, procaspase 3, and caspase 9 mainly through π-π interaction, with the CDOCKER interaction energy ranging from 10.3489 to 30.1231 kcal/mol (Table 1 and Figure 6A -D). There were five π-π interactions between tanshinone IIA and Bcl-xl at Arg139 and Phe105 and there were three π-π interactions between tanshinone IIA and Bak1 at Phe40. Tanshinone IIA also bound to procaspase 3 via π-π interaction at Arg15. There was no hydrogen bond formation, charge interaction, or π-π interaction between tanshinone IIA and Bax1 ( Figure 6 ). Similarly, tanshinone IIB interacted with human Bcl-xl, Bak1, procaspase 3, and caspase 9 mainly through π-π interaction, and to a lesser extent via hydrogen bond formation, with CDOCKER interaction energy ranging from 9.27765 to 35.7031 kcal/mol (Table 1 and Figure 7A -D). There were five π-π interactions between tanshinone IIB and Bcl-xl at Arg139 and Phe105 and three π-π interactions between tanshinone IIB and Bak1 at Phe40. Tanshinone IIB formed three hydrogen bonds with procaspase 3 at Ile17 and Gly92. Moreover, tanshinone IIB bound to procaspase 3 via π-π interactions at Arg15. There was also one π-π interaction between tanshinone IIB and caspase 9 ( Figure 7 ).
Danshensu interacted with human Bcl-xl, Bak1, Bcl-2, procaspase 3, and caspase 9, with CDOCKER interaction energy ranging from 13.0233 to 39.3839 kcal/mol (Table 1 and Figure 8A -E). Danshensu bound to Bcl-xl and Bak1 via hydrogen bond formation at Arg102 and Gln66, and π-π stacking at Arg139 and Phe40, respectively ( Figure 8 ). There was a π-π stacking between danshensu and Bcl-2 at Ile186. Furthermore, there were five hydrogen bonds formed at Ser14, Arg15, Gly18, and Asn90, two charge interactions at Arg15 and Asn37, and one π-π stacking at Arg15 between danshensu and procaspase 3. Moreover, danshensu bound to caspase 9 via hydrogen bond formation at Gln285, charge interaction, and π-π stacking at Arg180 (Figure 8 ).
Salvianolic acid A was docked into the active sites of human Bcl-xl, procaspase 3, and caspase 9 ( Figure 9A-C Arg95. Moreover, salvianolic acid A bound to caspase 9 via hydrogen bond formation at Arg180, Thr181, and Gln285 and π-π stacking at Arg178 and Arg180 ( Figure 9 ). Similarly, salvianolic acid C was docked into the active sites of human Bcl-xl, procaspase 3, and caspase 9 ( Figure 10A-C and π-π stacking at Arg102. Salvianolic acid C also formed seven hydrogen bonds with procaspase 3 at Gly18, Asn35, Asn37, Ala62, Val64, and Asn90, two charge interactions at Arg15 and Gly38, and two π-π stacking at Arg15. Moreover, salvianolic acid C bound to caspase 9 via hydrogen bond formation at Arg180, Gln285, Ser287, and Gly360, charge interaction at Asp186, and π-π stacking at Arg178 and Arg180 ( Figure 10 Molecular interactions between salvianolic acid a and human Bcl-xl, procaspase 3, and caspase 9 determined using Discovery studio ® program 3.1. Notes: (A) Bcl-xl (PDB iD: 4TUh), (B) procaspase 3 (PDB iD: 4JrO), and (C) caspase 9 (PDB iD: 2ar9). Abbreviation: PDB ID, Protein Data Bank identifier.
Protocatechuic aldehyde was also docked into the active sites of human Bcl-xl, Bak1, procaspase 3, and caspase 9, with CDOCKER interaction energy ranging from 11.8606 to 24.6477 kcal/mol (Table 1 and Figure 11A-D) . Protocatechuic aldehyde bound to Bcl-xl via hydrogen bond formation at Arg102 and Ser145 and interacted with Bak1 via π-π stacking at Phe40. Protocatechuic aldehyde also bound to procaspase 3 via hydrogen bond formation at Gly12, Arg15, Gly18, and Asn90 and via π-π stacking at Arg15. Moreover, there were two hydrogen bonds formed at Arg180 and Asp186 between protocatechuic aldehyde and caspase 9. There was no hydrogen bond formation, charge interaction, or π-π interaction between protocatechuic aldehyde and Bcl-2 ( Figure 11 ). β-boswellic acid was also bound to procaspase 3 and caspase 9 via hydrogen bond formation at Arg15 and Arg178, respectively ( Figure 12A and B). The CDOCKER interaction energy ranged from 31.6175 to 7.52648 kcal/ mol (Table 1) .
Taken together, the results showed that ferulic acid, ligustilide, succinic acid, vanillic acid, tanshinone IIA, tanshinone IIB, danshensu, salvianolic acid A, salvianolic acid C, protocatechuic aldehyde, and β-boswellic acid could bind to active sites of human Bcl-xl, Bak1, Bcl-2, procaspase 3, and caspase 9 via hydrogen bond formation, charge interaction, and/or π-π stacking. Ferulic acid, ligustilide, succinic acid, vanillic acid, tanshinone IIA, tanshinone IIB, danshensu, salvianolic acid A, salvianolic acid C, protocatechuic aldehyde, and β-boswellic acid may serve as enhancers or inhibitors of Drug Design, Development and Therapy 2015:9 submit your manuscript | www.dovepress.com
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hlXlD ameliorates ischemia-induced myocardial damage these key regulators of apoptosis, contributing to the beneficial effects of HLXLD in the treatment of IHD.
Predicted aDMeT properties of the major active components of hlXlD
The predicted ADMET properties of ferulic acid, ligustilide, succinic acid, vanillic acid, tanshinone IIA, tanshinone IIB, danshensu, salvianolic acid A, salvianolic acid B, salvianolic acid C, protocatechuic aldehyde, and β-boswellic acid using Discovery Studio ® program 3.1 are shown in Table 2 . Ferulic acid, ligustilide, succinic acid, and vanillic acid had very good aqueous solubility. The aqueous solubility value [log (molar solubility)] of ferulic acid, ligustilide, succinic acid, and vanillic acid was between 4 and 5 ( Table 2 ). However, they had a very low oral absorption. The blood-brain barrier permeability was between 3 and 4. Moreover, all properties and optimal prediction space (OPS) components of ferulic acid, ligustilide, succinic acid, and vanillic acid were within expected ranges with regard to the CYP2D6 interaction, hepatotoxicity, and plasma protein binding (Table 2) . Tanshinone IIA and tanshinone IIB showed ADMET profiles similar to those of ferulic acid, ligustilide, succinic acid, and vanillic acid, except for aqueous solubility and absorption. Tanshinone IIA and tanshinone IIA showed a very low aqueous solubility level of 0, but a good absorption at 1-2.
There were various predictions for the ADMET profile of salvianolic acid A, salvianolic acid B, salvianolic acid C, protocatechuic aldehyde, and β-boswellic acid, due to the presence of multiple poses generated. There were 42, 160, 52, 4, and 32 poses for salvianolic acid A, salvianolic acid B, salvianolic acid C, protocatechuic aldehyde, and β-boswellic acid, respectively (Table 2) . Salvianolic acid A, salvianolic acid B, salvianolic acid C, and protocatechuic aldehyde showed high aqueous solubility and a low absorption. All properties and OPS components of salvianolic acid A, salvianolic acid B, salvianolic acid C, and protocatechuic aldehyde were within expected ranges with regard to the CYP2D6 interaction and plasma protein binding, except for hepatotoxicity (Table 2) . β-boswellic acid showed a low aqueous solubility and a high absorption ( Table 2) .
effect of hlXlD on hemodynamic parameters in rats with coronary artery ligation-induced acute myocardial ischemia Next, we examined how HLXLD affected experimental IHD in rats. First, we examined the hemodynamic parameters in rats with coronary artery ligation-induced acute myocardial ischemia in the presence or absence of drug treatment. As shown in Tables 3 and 4 , there was a marked decrease in MAP, LVSP, LVEDP, heart rate, and ±dp/dt max in the model group of rats with coronary artery ligation-induced acute myocardial ischemia (P0.05 by one-way ANOVA), compared with the sham group. Administration of HLXLD marked improved the hemodynamic profile with a significant increase in MAP, LVSP, heart rate, and ±dp/dt max , compared with the model group. Moreover, the positive control group of rats administered isosorbide mononitrate 0.2 mg/kg also showed a marked beneficial effect on hemodynamics when compared with the model group. Taken together, HLXLD showed marked beneficial effects on coronary artery ligationinduced acute myocardial ischemia in rats.
effect of hlXlD on serum enzymes in rats with coronary artery ligationinduced acute myocardial ischemia Blood samples were analyzed after the rats has been treated for 4 weeks and the effect of HLXLD on key serum enzymes (SOD, CK, and LDH) was tested. There are three types of SOD in humans, including SOD1 in the cytoplasm, 24 SOD2 in the mitochondria, 25 and extracellular SOD3. 26 SODs have an important role in the maintenance of redox homeostasis and have been implicated in the pathogenesis of several diseases, including cardiovascular disease. 27 CK is a biomarker of myocardial infarction, and there are three isoenzymes of CK, including CK-MM, CK-BB, and CK-MB. 28, 29 LDH is of medical significance, acting as a 
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hlXlD ameliorates ischemia-induced myocardial damage marker for common injuries and disease. It is extensively expressed in body tissues, including in blood cells and heart muscle, and is released during tissue damage. 30 As shown in Table 5 , the model group had a slight decrease in serum SOD levels and a mild increase in serum CK and LDH levels, but the difference was not statistically significant (P0.05 by one-way ANOVA) when compared with the sham group. Furthermore, administration of HLXLD and isosorbide mononitrate did not have a significant effect on serum SOD, CK, and LDH levels (P0.05 by one-way ANOVA) when compared with the model group.
effect of hlXlD on pathological changes in rats with coronary artery ligationinduced acute myocardial ischemia To further evaluate the therapeutic effect of HLXLD in rats with coronary artery ligation-induced acute myocardial ischemia, a pathological examination was performed. As shown in Figure 13 , there were viable alterations in the morphology of the left ventricle. In the sham group, the cardiomyocytes were neatly arranged with no marked necrotic cell death or interstitial inflammatory cell infiltration ( Figure 13 ). In the model group with coronary artery ligation-induced acute myocardial ischemia, there was marked necrosis of cardiomyocytes in multiple areas, and the necrotic cardiomyocytes underwent myoplasm dissolution and vacuolation ( Figure 13 ). Furthermore, myocardial fibers were arranged in a disordered manner with a loose and disrupted structure, showing degeneration and breakage of the junctions between cardiomyocytes ( Figure 13 ). Administration of HLXLD had an ameliorating effect on coronary artery ligation-induced acute myocardial ischemia, as indicated by the amelioration and restoration in the disrupted morphology of the left ventricle ( Figure 13 ). Low-dose HLXLD (2.7 g/kg) slightly improved the arrangement of myocardial fibers and reduced focal necrosis of cardiomyocytes. Administration of mid-dose (5.4 g/kg) and high-dose (10.8 g/kg) HLXLD had a markedly beneficial effect on coronary artery ligation-induced damage in the left ventricle. The arrangement of the myocardial fibers was restored in a wave-like pattern and the disrupted myoplasm was recovered ( Figure 13 ). Moreover, in the positive group, rats administered isosorbide mononitrate 0.2 mg/kg showed amelioration of coronary artery ligation-induced tissue damage in the left ventricle ( Figure 13 ). The arrangement of myocardial fibers was restored in a wave-like pattern and the disrupted myoplasm was recovered in the positive group ( Figure 13 ). Taken together, the results indicate that HLXLD has a therapeutic effect on coronary artery ligation-induced tissue damage in the left ventricle in rats. Given the observed beneficial effects of HLXLD on coronary artery ligation-induced acute myocardial ischemia, we explored the molecular targets involved in this therapeutic effect. The molecular docking results showed potential interactions between the major active components of HLXLD and key regulators of apoptosis, so we tested the effect of HLXLD on the expression of caspase 3 and Bcl-2. As shown in Figure 14A and B, administration of HLXLD markedly altered the expression of key functional proteins, Bcl-2 and caspase 3, in heart tissue. Bcl-2 is an antiapoptotic protein antagonizing the apoptosis process and preventing cells from apoptotic cell death. 8 Caspase 3 is a key member of the caspase family and activation of caspase 3 is an indispensable step in mitochondria-dependent apoptosis. 10 Furthermore, it has been proposed that caspase 3 is a promising therapeutic target in the treatment of heart failure. 10 In comparison with the sham group, there was a 55.0% decline in expression of Bcl-2 (P0.05 by one-way ANOVA; Figure 14A and B), whereas there was a 2.9-fold increase in the level of cleaved caspase 3 in the model group (rats with coronary artery ligation-induced acute myocardial ischemia; P0.001 by one-way ANOVA; Figure 14A and B). Administration of HLXLD reversed these changes in Bcl-2 and cleaved caspase 3 expression. Compared with the model group, there was a 1.3-fold, 1.4-fold, and 1.5-fold increase in expression of 
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hlXlD ameliorates ischemia-induced myocardial damage Bcl-2; but a 39.5%, 34.9%, and 51.2% reduction in the level of cleaved caspase 3 when rats were administered HLXLD dosages of 2.7, 5.4, and 10.8 g/kg, respectively ( Figure 14A and B). Moreover, there was a comparable therapeutic effect of high-dose HLXLD in the positive control group treated with 0.2 mg/kg isosorbide mononitrate. Taken together, HLXLD increases the expression level of Bcl-2 and decreases the level of activated caspase 3 in rats with coronary artery ligationinduced acute myocardial ischemia, which may contribute to the therapeutic effect of HLXLD in the treatment of IHD.
Discussion
IHD remains the most common cause of death worldwide and its exact pathogenesis is unknown, 3 although the therapeutics currently available have greatly reduced the IHDrelated death rate. Increasing evidence shows that Chinese herbal medicines have beneficial effects in cardiovascular diseases. 31 In the present study, we predicted the binding modes of ferulic acid, ligustilide, succinic acid, vanillic acid, tanshinone IIA, tanshinone IIB, danshensu, salvianolic acid A, salvianolic acid B, salvianolic acid C, protocatechuic aldehyde, and β-boswellic acid with human Bcl-xl, Bak1, Bcl-2, procaspase 3, and caspase 9 using Discovery Studio ® program 3.1, examined their effects, and investigated the possible molecular targets of HLXLD, a traditionally Chinese herbal formula, in a rat model of coronary artery ligation-induced acute myocardial ischemia. Our findings show that HLXLD had substantial therapeutic effects on acute myocardial ischemia in rats. HLXLD attenuated the coronary artery-induced tissue damage and ameliorated and restored the disrupted morphology of the left ventricle in the rats, with a significant increase in the expression of Bcl-2 and a decrease in the level of cleaved caspase 3.
The molecular docking study using Discovery Studio ® program 3.1 showed that the major active components of HLXLD, including ferulic acid, ligustilide, succinic acid, vanillic acid, tanshinone IIA, tanshinone IIB, danshensu, salvianolic acid A, salvianolic acid C, protocatechuic aldehyde, and β-boswellic acid can be easily docked into the active sites of human Bcl-xl, Bak1, Bcl-2, procaspase 3, and caspase 9 via hydrogen bond formation, charge interaction, and/or π-π interaction. Ferulic acid, ligustilide, succinic acid, vanillic acid, danshensu, salvianolic acid A, salvianolic acid C, protocatechuic aldehyde, and β-boswellic acid interacted with human Bcl-xl, Bak1, Bcl-2, 
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han et al procaspase 3, and/or caspase 9 mainly through hydrogen bond formation, and to a lesser extent via charge interaction and/or π-π interaction, which may be due to the hydrophilic properties. In contrast, tanshinone IIA and tanshinone IIB bound to human Bcl-xl, Bak1, procaspase 3, and/or caspase 9 mainly via π-π interaction, due to the hydrophobic properties. Indeed, the ADMET Predictor in Discovery Studio ® program 3.1 predicted differential aqueous solubility of these components, which further explains the differential molecular interactions. In contrast, salvianolic acid B cannot be docked into the active sites of human Bcl-xl, Bak1, Bcl-2, procaspase 3, or caspase 9, due to violation of the "rule of five". Taken together, the molecular interactions between the major active components of HLXLD and the key regulators of apoptosis suggest a potential regulatory effect of HLXLD on apoptosis.
Myocardial ischemia is a clinical condition in which coronary blood flow is reduced by a variety of factors, such as accumulation of fatty deposits (atheroma) in the cells lining the wall of the coronary arteries. 32, 33 This results in a limited myocardial oxygen supply and decreased clearance of metabolites. 32, 33 In the clinic, myocardial ischemia is mainly related to a reduction of coronary blood flow. Any factors that reduce coronary perfusion pressure and/or increase coronary vascular resistance can cause insufficiency of the coronary artery blood supply and myocardial ischemia. 32, 33 When cardiac muscle undergoes ischemia and hypoxia, cardiac physiology and biochemistry will correspondingly change.
Under conditions of myocardial ischemia, regional myocardial contraction and relaxation is disrupted, as indicated by decreased myocardial contractility and cardiac output, a decrease in ±dp/dt max , and an increase in LVEDP. 34, 35 MAP and ±dp/dt max reflect left ventricular and arterial systolic and diastolic function; 32, 36 of these, ±dp/dt max is a sensitive indicator of changes in myocardial diastolic parameters and function. 26, 30 Reduction of diastolic coronary pressure will lead to further aggravation of myocardial ischemia, leading to IHD. The most common cause of IHD is coronary atherosclerosis, and the left anterior descending coronary artery is most commonly involved vessel. Ligation of the left anterior descending coronary artery will cause a serious shortage of myocardial blood supply and a sharp decline in cardiac function, leading to a marked decrease in MAP, LVSP, heart rate, and ±dp/dt max . 32, 37 In the present study, we have demonstrated that administration of HLXLD mitigates the decrease in MAP, LVSP, heart rate, and ±dp/dt max in rats with acute myocardial ischemia. Our observations indicate that HLXLD has a beneficial effect on coronary artery ligation-induced dysfunction in the rat heart. Furthermore, we examined the effect of administration of HLXLD on serum SOD, CK, and LDH, which are important indicators for clinical detection of the extent and scope of myocardial ischemia. 27, 28, 30 SOD is an important radical scavenger in the human body, playing a role in the clearance of superoxide ions. 27 Abnormalities in its activity and/ or expression have been implicated in the pathogenesis of many diseases, including those affecting the cardiovascular system. 27 Under conditions of acute myocardial ischemia, SOD can protect myocardial cells from invasion by free oxygen radicals, maintain the integrity of the myocardial cell membrane, and reduce the damage caused by ischemia. 27 CK and LDH are two enzymes present in myocardial cells, and act as biomarkers of myocardial infarction. [28] [29] [30] Acute myocardial ischemia can cause hypoxic injury to a large number of myocardial cells, resulting in substantial release of CK and LDH into the blood. In our study, no significant difference was observed in these parameters, which may be because they were measured 4 weeks after coronary artery ligation was performed. However, pathological examination showed that administration of HLXLD markedly attenuated the ischemia-induced tissue damage, improved the arrangement of myocardial fibers, and reduced the focal necrosis of cardiomyocytes in rats. Overall, the results indicate that HLXLD has a therapeutic effect on IHD in rats.
Apoptosis is a fundamental biological phenomenon in cells, with an essential role in removing unwanted or abnormal cells in multicellular organisms. 38, 39 Apoptosis is not only a special type of cell death but also has great biological significance and involves complex molecular mechanisms. 38, 39 In particular, apoptosis is a key feature in the progression of heart disease and has an important role in adverse ventricular remodeling. 6, 40, 41 Many factors can cause apoptosis, including a variety of ischemia, hypoxia, and toxicity factors, and the process of apoptosis involves a large number of proteins, including the caspase family. 38, 39, 41 Caspases are a class of cysteine proteases that contain abundant cysteine at the active site and specifically catalyze hydrolysis of the aspartate portion in the substrate. 42, 43 Caspases are widely distributed in cells of various tissues, and their normal expression induces apoptosis. Caspase 3 is a key protease involved in apoptosis, acting as an executor and terminator of apoptosis, as well as a marker enzyme for occurrence of apoptosis. 42, 43 Furthermore, it has been proposed that caspase 3 may represent a promising therapeutic target in the treatment of cardiovascular disease. 10 The Bcl-2 family is another group of proteins involved in apoptosis, members of which have antiapoptotic effects as well as proapoptotic effects. 8 In different types of cells, Bcl-2
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hlXlD ameliorates ischemia-induced myocardial damage can be located in the mitochondria, endoplasmic reticulum, and nuclear membrane, where it plays a role in antiapoptosis by preventing the release of mitochondrial cytochrome c. 8 In addition, Bcl-2 has a protective effect on cells, and its overexpression can reduce caspase activity. 8 In the present study, our results show that administration of HLXLD markedly decreased the ischemia-induced activation of caspase 3 while increasing the expression of Bcl-2 in rats. These results indicate that HLXLD effectively inhibits apoptosis and protects myocardial cells against death, contributing to the therapeutic effect of HLXLD on coronary artery ligationinduced acute myocardial ischemia in rats.
Notably, there are a number of pharmacologically active components in HLXLD, such as tanshinones and salvianolic acids, which have been demonstrated to be protective cardiovascular components in vitro and in vivo. 18, 44, 45 Their beneficial effects include improving the microcirculation, causing coronary vasodilatation, suppressing formation of thromboxane, and inhibiting platelet adhesion and aggregation, involving a number of important functional proteins and related signaling pathways, such as phosphatidylinositol-4, 5-bisphosphate 3-kinase/Akt signaling pathways. 18, 45 Our computational study showed that ferulic acid, ligustilide, succinic acid, vanillic acid, tanshinone IIA, tanshinone IIB, danshensu, salvianolic acid A, salvianolic acid C, protocatechuic aldehyde, and β-boswellic acid could interact with human Bcl-xl, Bak1, Bcl-2, procaspase 3, or caspase 9 via hydrogen bond formation, charge interaction, and/or π-π interaction. Collectively, the results suggest that the therapeutic effect of HLXLD may be, at least in part, ascribed to the above-mentioned mechanisms of action of its bioactive components.
In summary, we have observed that the major active components of HLXLD interact with human Bcl-xl, Bak1, Bcl-2, procaspase 3, or caspase 9 via hydrogen bond formation, charge interaction, and/or π-π interaction using Discovery Studio ® program 3.1. HLXLD mitigated the hemodynamic and serum enzyme changes induced by coronary artery ligation-induced acute myocardial ischemia, attenuated ischemia-induced tissue damage, and ameliorated myocardial function in rats. Furthermore, HLXLD inhibited apoptosis of cardiomyocytes by increasing the expression of Bcl-2 and decreasing the level of cleaved caspase 3 in rats with acute myocardial ischemia. Our findings suggest that HLXLD may be a promising agent for the treatment of IHD via targeting of apoptosis. More functional and mechanistic studies are warranted to elucidate the possible mechanisms involved, identify the therapeutic targets, and verify the efficacy and safety of HLXLD in the treatment of IHD.
